Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
875 participants
INTERVENTIONAL
2010-09-30
2013-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The US Department of Health and Human Services granted $3 million in funding, with additional support provided by member institutional and private foundations. A total of nine hospitals in the United States and Canada will serve as data collection sites for the study (see list below). Staggered six-month waves of baseline data collection of medical errors and resident workflow, satisfaction, and miscommunications began in January 2010. Each site has a six-month wash-in period to implement the RHB intervention before embarking upon an additional six months of post-intervention data collection. Analysis and dissemination will begin upon completion of data collection at the last wave of sites in April 2013.
Study Sites:
Children's Hospital Boston (Boston, MA) - Coordinating Site Brigham and Women's Hospital (Boston, MA) - Data Coordinating Center
Lucile Packard Children's Hospital (Palo Alto, CA) UCSF Benioff Children's Hospital (San Francisco, CA) OHSU Doernbecher Children's Hospital (Portland, OR) Primary Children's Medical Center (Salt Lake City, UT) St. Louis Children's Hospital (St. Louis, MO) Cincinnati Children's Hospital Medical Center (Cincinnati, OH) Hospital for Sick Children (Toronto, ON) National Capital Consortium (Washington, DC) St. Christopher's Hospital for Children (Philadelphia, PA)
Study Leadership:
Principal Investigator: Christopher Landrigan, MD, MPH Project Leader: Amy Starmer, MD, MPH
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
HEALTH_SERVICES_RESEARCH
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Resident Handoff Bundle
bundle of interventions designed to improve handoff, including: training of residents in teamwork and handoff techniques; redesign of verbal handoff processes; implementation of handoff mnemonic (I-PASS); implementation of structured written / computerized handoff tool; faculty training in handoffs
Resident Handoff Bundle
1\) team training, 2) verbal mnemonics, and 3) standardization of written/computerized handoff tools
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Resident Handoff Bundle
1\) team training, 2) verbal mnemonics, and 3) standardization of written/computerized handoff tools
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* All resident physicians rotating through study teams during the two 6 month periods of data collection will be included in the study if informed consent is granted. No resident physicians will be excluded on the basis of age, gender, ethnicity, race, or other demographic features. We anticipate enrolling a maximum of 70 resident physicians per site. This number may be significantly less due to the fact that certain residents may rotate through data collection study units more than once during the study period.
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Lucile Packard Children's Hospital
OTHER
University of California, San Francisco
OTHER
Primary Children's Hospital
OTHER
St. Louis Children's Hospital
OTHER
Children's Hospital Medical Center, Cincinnati
OTHER
St. Christopher's Hospital for Children
OTHER
Walter Reed National Military Medical Center
FED
The Hospital for Sick Children
OTHER
OHSU Doernbecher Children's Hospital
OTHER
Boston Children's Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Christopher Landrigan
Research Director, Children's Hospital Boston Inpatient Pediatrics Service Director, Sleep and Patient Safety Program, Brigham and Women's Hospital Associate Professor of Medicine and Pediatrics, Harvard Medical School
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christopher P Landrigan, MD, MPH
Role: PRINCIPAL_INVESTIGATOR
Boston Children's Hospital
Amy J Starmer, MD, MPH
Role: STUDY_DIRECTOR
Oregon Health and Sciences University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Lucile Packard Children's Hospital
Palo Alto, California, United States
UCSF Benioff Children's Hospital
San Francisco, California, United States
Walter Reed National Military Medical Center
Bethesda, Maryland, United States
Brigham and Women's Hospital
Boston, Massachusetts, United States
Children's Hospital Boston
Boston, Massachusetts, United States
St. Louis Children's Hospital
St Louis, Missouri, United States
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States
St. Christopher's Hospital for Children
Philadelphia, Pennsylvania, United States
Primary Children's Medical Center
Salt Lake City, Utah, United States
Hospital for Sick Children
Toronto, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
X10-08-0392
Identifier Type: -
Identifier Source: org_study_id